الصفحة 2
الصفحة 2
Comparative Hepatitis
This volume reviews today’s knowledge about hepatitis with emphasis on comparative aspects between hepatitis in humans and animals, but also between different etiological agents. This particular viewpoint makes the book relevant for scientists from both human and veterinary medicine, gastroenterologists, pathologists, virologists and students of human and veterinary medicine.
Clinical microbiology made ridiculously simple
Is a brief, clear, thorough, and updated approach to clinical microbiology, brimming with mnemonics, humor, summary charts, and illustrations. Topics include Ebola, AIDS, flesh-eating bacteria, mad cow disease, hantavirus, anthrax, smallpox, and tuberculosis; the latest antibiotics; pandemic flu, including H7N9; SARS-like coronavirus; hepatitis C treatment options; HIV diagnostics and approved HIV meds; Zika virus; measles; and a new chapter on the latest emerging infectious diseases and drug-resistant bacteria. The major update to this book is the addition of a new chapter on the SARS-COV-2 virus and COVID-19 disease, which delves into the nature of the virus such as infectivity within the body, transmission between individuals, timeline of infectivity, symptoms, risk factors, therapeutics, and vaccines approved for use.
Cholestatic Liver Disease
Cholestatic Liver Disease provides essential information for individuals involved in the care of patients affected by cholestatic liver disease. This groundbreaking text also supplies scientific updates from leading experts which relate to the clinical evaluation and management of cholestatic liver disorders, useful for both novice and practitioners alike.
Cancer drug safety and public health policy : A changing landscape
Description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. Opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention – these fines are playing an important role in changing the landscape for pharmaceutical safety.
